Benefits
Knee comfort studied in adults with knee osteoarthritis
Theracurmin itself was tested: 50 adults over 40 with knee osteoarthritis took 180 mg of curcumin a day or placebo for 8 weeks, and 41 were analysed. Knee pain improved more than on placebo only after leaving out 6 people with very little pain at the start; across all 41 the difference was not significant (p = 0.10). Fewer needed celecoxib at week 8. One small trial, funded by the maker, and not a treatment for osteoarthritis.
Exercise recovery: not measured in the cited studies
None of the trials cited on this page looked at exercise, muscle damage or recovery, so there is no evidence here for a training or recovery benefit.
Blood vessel function: not measured in the cited studies
No blood vessel or circulation outcome was measured in any study cited on this page. Nothing on this page supports a heart or blood vessel claim.
Amyloid and tau scan results: research markers only
The 18-month memory trial cited on this page also ran brain scans for amyloid and tau, proteins studied in Alzheimer's disease research, in 30 of its participants. Signals in one brain region differed from placebo, but these are research markers in a small group, not a benefit a supplement can claim, and Theracurmin is not a treatment for dementia.
Better absorption than plain curcumin (manufacturer figure)
The colloidal nanoparticle form is designed to get more curcumin into the blood than plain curcumin powder, which is why the doses are small. The absorption figures come from the manufacturer and are not from any study cited on this page. Better absorption is a property of the ingredient, not a health benefit in itself.
Immune and inflammatory measures: studied, but results not detailed
The cold trial cited here did measure immune and inflammatory function alongside cold symptoms, in healthy Japanese adults taking 150 mg a day for 12 weeks. The published summary reports only the cold symptom result in detail, so the inflammatory findings should not be overstated. No specific drop in CRP or IL-6 is documented by any reference on this page.
Liver: no liver study is cited here
No study cited on this page set out to measure the liver. Fatty liver disease is a medical condition diagnosed and managed by a doctor, and nothing referenced here shows that this supplement changes liver enzymes or liver fat.
Memory and attention in older adults over 18 months
Theracurmin itself was tested: 40 adults aged 51 to 84 without dementia took 90 mg of curcumin twice a day or placebo for 18 months. A verbal memory retrieval score (effect size 0.68, p = 0.05) and an attention test (effect size 0.67, p = 0.04) improved more than on placebo; visual memory gains were reported within the curcumin group. One small trial, and the brain scan results are research markers only.
Knee cartilage quality studied after cartilage repair surgery
Theracurmin itself was tested: 50 adults having mosaicplasty, a knee cartilage repair operation, took 180 mg of curcumin a day or placebo for 12 months, and 43 were examined. Pain and knee function scores and MRI cartilage mapping did not differ from placebo. Cartilage stiffness and surface roughness in parts of the knee, checked at a follow-up arthroscopy, were better on curcumin. A single trial, funded by the maker.
Mechanism of action
Colloidal nanoparticle dispersion (how the form differs)
Curcumin (diferuloylmethane) is dispersed with colloidal nanoparticles via Theravalues' proprietary manufacturing process. The maker says the nanoparticle form helps curcumin cross the gut lining, which plain crystalline curcumin does poorly because it barely dissolves in water. It is a different approach from other enhanced-absorption curcumin forms such as Meriva, Longvida, BCM-95 and CurQfen. None of these absorption comparisons come from a study cited on this page.
Increased intestinal endothelium penetrability
Nanoparticle dispersion is intended to help curcumin pass through the gut wall, which plain crystalline curcumin struggles to do because it hardly dissolves in water. This is the manufacturer's explanation for the higher blood levels; no absorption study is cited on this page.
NF-κB anti-inflammatory pathway suppression
Curcumin's core anti-inflammatory mechanism via NF-κB pathway suppression. This pathway work comes from laboratory research on curcumin in general, not from any human study of this branded product cited on this page.
Getting into the brain (proposed, not shown here)
It is proposed that the better absorbed form reaches the brain more easily than plain curcumin. No study cited on this page measured curcumin levels in the brain, so this remains a theory, even though the 18-month trial cited here did measure memory and attention.
Amyloid and tau (dementia research, not cited here)
The 18-month memory trial cited on this page ran exploratory amyloid and tau brain scans in 30 participants, and one region differed from placebo. Amyloid and tau are markers studied in dementia research, and a small scan result does not show that this supplement affects any disease process.
Antioxidant via direct ROS scavenging and Nrf2 activation
Curcumin can neutralize reactive oxygen species and switch on the Nrf2 antioxidant pathway in laboratory studies. Whether this happens in people at the doses used is not shown by any study cited on this page.
Clinical trials
Cold symptoms and immune measures in healthy Japanese adults.
Clinical population described in trial publication.
Kuwabara Y and colleagues, Journal of Dietary Supplements 2024 (PMID 36927282). Randomized, double-blind, placebo-controlled trial in healthy Japanese adults; 94 people completed it (30 on placebo, 32 on Theracurmin Super TS-P1, 33 on Theracurmin CR-033P) taking 150 mg a day for 12 weeks. Both curcumin groups had significantly fewer total days with cold symptoms than placebo. Immune and inflammatory function was also measured, but the published summary details only the cold symptom result, so those findings should not be overstated. No memory, joint or liver outcome was measured in this study.
Theravalues 6-month MCI/AD stabilization trial (n=93).
Clinical population described in trial publication.
This is a manufacturer-reported study with no publication, no reference and no PMID on this page, so its results cannot be checked. It was run in people already diagnosed with mild cognitive impairment or Alzheimer's disease, which is a medical setting and says nothing about what a supplement does for a healthy person. Treat it as a company claim, not as evidence.
UCLA-sponsored Phase 2 12-month cognitive trial using Theracurmin Super TS-P1 75 mg/day.
Clinical population described in trial publication.
A university-sponsored 12-month study of Theracurmin Super at 75 mg a day was withdrawn by its sponsor before enrolling anyone, according to its registry entry. No participants were enrolled, so no data and no results exist. It is not evidence of anything.